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The effects of succinylacetone, a tyrosine metabolite, on the hepatic biosynthesis of heme and cytochrome 
P450 were studied in primary culture of chick embryo hepatocytes. Succinylacetone potentiated the 
phenobarbital-mediated induction of S-aminolevulinate synthase, strongly inhibited porphobilinogen 
synthase activity, reduced cellular heme concentration and impaired induction of cytochrome P450. 
Enhanced induction of &aminolevulinate synthase and decreased cytochrome P450 induction may be 
explained by the succinylacetone-mediated inhibition of porphobilinogen synthase and the subsequent 
depletion of intracellular heme, since these effects of succinylacetone were reversed by addition of heme. 
These results suggest clinical implications for patients with tyrosinemia, who accumulate succinylacetone. 
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1. INTRODUCTION 
Succinylacetone (SA, 4,6-dioxoheptanoic acid), 
a metabolite of tyrosine, accumulates in patients 
with hereditary tyrosinemia presumably due to a 
decreased activity of fumarylacetoacetase [ 11. Re- 
cent studies suggest hat SA is a potent, irreversible 
inhibitor of porphobilinogen (PBG) synthase (EC 
4.2.1.24), the second enzyme of heme synthesis, by 
binding to the active site of the enzyme [2]. The in- 
hibition of PBG synthase by SA in patients with 
tyrosinemia leads both to excessive accumulation 
and excretion of &aminolevulinate (ALA) and is 
associated with the occurrence of neurological 
symptoms characteristic of acute attacks of hepatic 
porphyria. Thus, the defect in hereditary 
tyrosinemia seems to alter yet another important 
metabolic pathway, the biosynthesis of heme [l]. 
This study was designed to examine the effects 
of SA on the biosynthesis of heme and hemopro- 
teins in the liver. Heme synthesis is mainly con- 
trolled by negative-feedback regulation of the first 
enzyme of the pathway, ALA synthase (EC 
2.3.1.37) [3]. In the liver > 60% of the heme syn- 
thesized is required to maintain cytochrome P450 
hemoprotein concentration, the key component of 
the microsomal drug oxidation system. Moreover, 
induction of cytochrome P450 hemoproteins by 
drugs and other chemicals is associated with an in- 
crease in hepatic ALA synthase activity and heme 
biosynthesis presumably by decreasing a 
regulatory cellular heme pool [3-51. We have used 
chick embryo hepatocytes cultured under 
chemically defined conditions. This culture system 
uniquely preserves inducibility of ALA synthase 
[3] and cytochrome P450 hemoproteins by drugs, 
such as phenobarbital [6-81. 
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2. EXPERIMENTAL 
Hepatocytes were isolated from 15day-old 
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chick embryos (Shaver hybrids) by in situ perfu- 
sion of the liver and collagenase digestion, and 
1.5 x IO’ cells were cultured in 10 ml serum-free 
Williams’ E medium containing 2.5 mM glucose 
and 1.5 FM triiodothyronine in IO cm Falcon 
culture dishes for 44 h as in [S]. The medium was 
changed after 24 h culture. SA dissolved in 
medium (neutralized and filtered through 0.22 pm 
millipore filters) was present for the last 20 h 
culture and 0.4 mM phenobarbital was added for 
the final 16 h culture (induction period). Heme 
was dissolved in 0.25% sodium carbonate (pH 8.0) 
and was administered twice, 2 h before and 4 h 
after the addition of phenobarbital to reach 3 pM 
final cont. 
For the preparation of homogenate and 
microsomes, hepatocyte monolayers from 3 
culture dishes were washed twice with 0.25 M 
sucrose, scraped off the dishes, homogenized and 
sonicated in 2 ml sucrose at 4°C as in [8]. 
Microsomes were prepared from 1.4 ml of this 
homogenate. The remaining homogenate and 
microsomes uspended in 0.1 M sodium phosphate 
buffer (pH 7.4) were stored at - 20°C. ALA syn- 
thase activity was determined as in [9] with some 
modifications [8]. PBG synthase activity was 
measured as in [lo] with the following modifica- 
tions: The incubation mixture consisted of 0.1 ml 
homogenate and 0.4 ml 0.1 M sodium phosphate 
buffer containing 5 pmol ALA and 1.5 pmol 
reduced glutathione (pH 6.3). After incubation for 
45 min the reaction was stopped with 0.5 ml 4% 
trichloroacetic acid-2.7% HgClt. An equal 
volume of modified Ehrlich’s reagent was added to 
the supernatant after centrifugation and the A556 
was measured after 15 min. When cultures or 
homogenates were treated with SA, non-enzymatic 
formation of a pyrrole from SA and ALA was 
observed. Total cellular heme concentration was 
determined by the oxalic acid-fluorimetric pro- 
cedure as in [ 111. Microsomal cytochrome P450 
concentration was measured in microcuvettes ac- 
cording to [6] and protein concentrations were 
determined by the Lowry method 1121. 
3. RESULTS 
In cultured chick embryo hepatocytes phenobar- 
bital increased ALA synthase activity (Zfold) and 
cytochrome P450 concentration (Zfold), whereas 
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PBG synthase activity remained unchanged. Addi- 
tion of SA increased the phenobarbital-mediated 
induction of ALA synthase, strongly inhibited 
PBG synthase activity and decreased cytochrome 
P450 concentration. In control cultures, not expos- 
ed to phenobarbital, the effects of SA on heme 
synthesis and cytochrome P450 were similar, but 
not as pronounced as when induction causes 
enhanced intracellular heme requirement for the 
synthesis and assembly of cytochrome P450 
hemoproteins (fig.1). The effect of SA on ALA 
synthase and on cytochrome P450 concentrations 
in monolayers exposed to phenobarbital was dose- 
dependent (fig.2). Furthermore, the 
phenobarbital-mediated increase in total cellular 
heme was also reduced by SA in a dose-dependent 
- 
Fig.1. Effect of succinylacetone on ALA synthase and 
PBG synthase activities and cytochrome P450 
concentration in hepatocyte culture. Hepatocyte 
monolayers were exposed to SA and/or phenobarbita1 
(0.4 mM) for the final 20 h or 16 h of a 44 h culture 
period, respectively. Heme (3 PM) was added twice 18 h 
and 12 h prior to the preparation of homogenate and 
microsomes. Each bar represents the mean t SE of 3-4 
independent expt: (0) phenobarbital-treated cultures; 
( q ) control (no phenobarbital treatment). 
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Fig.2. Dose-response of succinylacetone on ALA 
synthase and PBG synthase activities, cellular heme and 
cytochrome P450 concentration in hepatocyte cultures 
treated with phenobarbital. Hepatocytes were exposed 
to SA for the last 20 h of culture, and phenobarbital 
(0.4 mM) was added for the final 16 h. Each point 
represents the mean f SE of 3-4 independent expt. 
manner towards basal cellular heme concentra- 
tions (control content 299 f 16 pmol heme/mg 
protein, n = 4), parallel to the impaired 
phenobarbital-mediated induction of cytochrome 
P450 by SA (fig.2). 
The inhibition of heme synthesis at the level of 
PBG synthase by SA in hepatocyte culture could 
be overcome by the addition of exogenous heme 
(fig.1). Heme alone did not affect PBG synthase 
activity or cytochrome P450 concentration, but 
suppressed the phenobarbital-mediated induction 
of ALA synthase. However, the SA-mediated in- 
hibition of cytochrome P450 induction by 
phenobarbital was almost completely reversed by 
adding exogenous heme to the medium. Moreover, 
heme entirely repressed the increase of ALA syn- 
thase activity by SA. 
4. DISCUSSION 
The present study in cultured chick embryo 
hepatocytes demonstrates that succinylacetone is 
an extremely potent inhibitor of hepatic heme syn- 
thesis at the level of PBG synthase. Moreover, our 
data suggest that impaired phenobarbital-mediated 
induction of cytochrome P450 and an enhanced in- 
duction of ALA synthase may both be explained 
by the depletion of intracellular heme, since these 
effects of SA were reversed by exogenous heme. 
These studies confirm and extend observations on 
the effect of SA in rats in vivo [2]. 
In hepatocytes, the second enzyme of heme 
biosynthesis, PBG synthase, which catalyses the 
conversion of two &aminolevulinate into por- 
phobilinogen, is present in considerable excess in 
relation to the rate-limiting enzyme of this 
pathway. Therefore, PBG synthase activity has to 
be strongly inhibited to affect heme synthesis. At 
10yM SA, this enzyme activity was > 95% in- 
hibited, but cellular heme concentration and 
cytochrome P450 induction were only minimally 
altered. The enzyme activity apparently was fur- 
ther inhibited by increasing the concentration of 
SA in the culture medium as indicated by the dose- 
dependent enhanced induction of ALA synthase, 
the progressively impaired induction of 
cytochrome P450 and the loss of cellular heme. In 
contrast to ALA synthase, the activity of PBG syn- 
thase appears to be neither increased by phenobar- 
bital nor inhibited by exogenous heme in cultured 
chick embryo hepatocytes. 
Other inhibitors of hepatic PBG synthase activi- 
ty, such as lead [13], levulinate, 3-amino-1,2,4- 
triazole, EDTA [2] or L-Zamino-4-methoxy- 
trans-3-butenoic acid [14] are either less potent or 
less specific than SA [2]. As with other inhibitors 
of heme synthesis [8], the effect of SA on ALA 
synthase was potentiated by simultaneous ex- 
posure to phenobarbital, which induces apocy- 
tochrome P450 [7,8,15]. It is likely that this ex- 
tensive induction of ALA synthase is caused by the 
combination of an extremely restricted cellular 
heme pool through SA-mediated inhibition of 
heme production and enhanced consumption of 
heme for the assembly of cytochrome P450 hemo- 
proteins. This striking induction of ALA synthase 
has been observed with other inhibitors of heme 
synthesis given in combination with inducers of 
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